Join our email list to stay up to date on the latest Amyloidosis news.
July 7, 2021

CRISPR technology offers a cutting-edge approach to gene-editing. New clinical findings from Intellia’s Phase 1 trial have demonstrated for the first time that CRISPR can be administered by infusion to target specific cells within the body.

(more…)

*

*

*

*